Morphic Therapeutic Announces First Healthy Volunteers Dosed in Phase 1 Clinical Trial of MORF-057
First orally available integrin inhibitor from MInT Platform to enter the clinic
MORF-057, inhibitor of
α4β7 integrin, in development to treat inflammatory bowel
disease
Phase 1 program to assess safety and pharmacokinetics of MORF-057 as well as
α4β7 receptor occupancy as a clinically relevant
biomarker
WALTHAM, Mass., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that the first healthy volunteers have received MORF-057 in a phase 1 clinical trial designed to evaluate MORF-057’s safety and pharmacokinetic profile in addition to predictive pharmacodynamic signals. MORF-057 is in clinical development as an oral small molecule inhibitor of the α4β7 integrin for the treatment of inflammatory bowel disease (IBD) with an initial focus on ulcerative colitis (UC).
“Morphic designed MORF-057 with its MInT Platform, a unique platform for the discovery and development of oral integrin drugs, to be a highly selective and potent orally administered inhibitor of the α4β7 integrin, a well-validated target in IBD. The initiation of clinical trials for MORF-057 marks a major step forward in this effort,” stated Dr. Peter Linde, MD, chief medical officer of Morphic Therapeutic. “Based on its extensive preclinical data package, we believe that MORF-057 can selectively target the same clinically validated mechanism as the approved injectable antibody, vedolizumab, but utilizing a substantially more convenient oral small molecule. The MORF-057 phase 1 trial is designed to generate safety and pharmacokinetic data, as well as to provide key measures of α4β7 receptor occupancy, at multiple doses being evaluated in this program. These results may provide early clinical proof-of-concept for MORF-057 and we expect to present these data at a major medical conference in the first half of next year.”
Lesen Sie auch
About the MORF-057 Phase 1 Clinical Trial
The phase 1 clinical trial is designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of MORF-057 dosed twice daily across three parts enrolling at least 76 healthy volunteers. The
initial part of the phase 1 trial will evaluate single ascending doses in 40 or more volunteers across five or more dose cohorts of MORF-057. The second part of the trial will evaluate multiple
ascending doses in 24 or more volunteers across at least three dose cohorts of MORF-057. A third part will evaluate the effect of food on the pharmacokinetic effects of MORF-057 in two cohorts of
six subjects, each receiving MORF-057 in fed and fasting states. The phase 1 program is designed to generate important receptor occupancy data in each dose cohort that could potentially provide
early clinical proof-of-concept and dose selection guidance for use in future studies of MORF-057.